GLP-1s appear safe for treating diabetes in pregnancy, but evidence gaps remain

New research suggests that the use of GLP-1 receptor agonist (GLP-1 RA) drugs for diabetes and weight management in women with diabetes during pregnancy appears to be safe, according to a review published in The Lancet Obstetrics, Gynaecology & Women's Health. However, significant gaps in evidence remain regarding the impact of these drugs on fertility, pregnancy, and maternal and child health.

The international panel of authors, including Professor Claire Meek from the Leicester Diabetes Research Center, emphasized the need for more research to address these gaps and keep up with the growing number of women of reproductive age using GLP-1 RAs. Diabetes prevalence in pregnancy continues to rise globally, making it crucial to optimize maternal metabolic health before conception.

The meta-analysis of over 43,000 participants found no significant associations between GLP-1 RA exposure and the risk of preterm birth, stillbirth, neonatal death, cesarean section, pregnancy hypertensive disorders, or preeclampsia. Early pregnancy loss was slightly more common among exposed women, but this finding requires caution due to the potential for deliberate termination or miscarriage to be counted as the same outcome.

While the evidence suggests no increased risk of congenital anomalies following first-trimester discontinuation of GLP-1 RAs, further research is needed to fully understand the long-term effects of these drugs on maternal, fetal, and infant health.